Cargando…

YM500v2: a small RNA sequencing (smRNA-seq) database for human cancer miRNome research

We previously presented YM500, which is an integrated database for miRNA quantification, isomiR identification, arm switching discovery and novel miRNA prediction from 468 human smRNA-seq datasets. Here in this updated YM500v2 database (http://ngs.ym.edu.tw/ym500/), we focus on the cancer miRNome to...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheng, Wei-Chung, Chung, I-Fang, Tsai, Cheng-Fong, Huang, Tse-Shun, Chen, Chen-Yang, Wang, Shao-Chuan, Chang, Ting-Yu, Sun, Hsing-Jen, Chao, Jeffrey Yung-Chuan, Cheng, Cheng-Chung, Wu, Cheng-Wen, Wang, Hsei-Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4383957/
https://www.ncbi.nlm.nih.gov/pubmed/25398902
http://dx.doi.org/10.1093/nar/gku1156
Descripción
Sumario:We previously presented YM500, which is an integrated database for miRNA quantification, isomiR identification, arm switching discovery and novel miRNA prediction from 468 human smRNA-seq datasets. Here in this updated YM500v2 database (http://ngs.ym.edu.tw/ym500/), we focus on the cancer miRNome to make the database more disease-orientated. New miRNA-related algorithms developed after YM500 were included in YM500v2, and, more significantly, more than 8000 cancer-related smRNA-seq datasets (including those of primary tumors, paired normal tissues, PBMC, recurrent tumors, and metastatic tumors) were incorporated into YM500v2. Novel miRNAs (miRNAs not included in the miRBase R21) were not only predicted by three independent algorithms but also cleaned by a new in silico filtration strategy and validated by wetlab data such as Cross-Linked ImmunoPrecipitation sequencing (CLIP-seq) to reduce the false-positive rate. A new function ‘Meta-analysis’ is additionally provided for allowing users to identify real-time differentially expressed miRNAs and arm-switching events according to customer-defined sample groups and dozens of clinical criteria tidying up by proficient clinicians. Cancer miRNAs identified hold the potential for both basic research and biotech applications.